BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nakamura K, Nakabayashi K, Htet Aung K, Aizawa K, Hori N, Yamauchi J, Hata K, Tanoue A. DNA methyltransferase inhibitor zebularine induces human cholangiocarcinoma cell death through alteration of DNA methylation status. PLoS One 2015;10:e0120545. [PMID: 25799509 DOI: 10.1371/journal.pone.0120545] [Cited by in Crossref: 42] [Cited by in F6Publishing: 46] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Arakelyan J, Rusanov DA, Chang MR, Asaturova AV, Kireeva GS, Alshehri M, Ang WH, Babak MV. Targeting emerging cancer hallmarks by transition metal complexes: Epigenetic reprogramming and epitherapies. Part II. Coordination Chemistry Reviews 2023;475:214899. [DOI: 10.1016/j.ccr.2022.214899] [Reference Citation Analysis]
2 Basha NJ, Basavarajaiah SM. An insight into therapeutic efficacy of heterocycles as histone-modifying enzyme inhibitors that targets cancer epigenetic pathways. Chem Biol Drug Des 2022. [PMID: 36059065 DOI: 10.1111/cbdd.14135] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Hu S, Molina L, Tao J, Liu S, Hassan M, Singh S, Poddar M, Bell A, Sia D, Oertel M, Raeman R, Nejak-Bowen K, Singhi A, Luo J, Monga SP, Ko S. NOTCH-YAP1/TEAD-DNMT1 Axis Drives Hepatocyte Reprogramming Into Intrahepatic Cholangiocarcinoma. Gastroenterology 2022;163:449-65. [PMID: 35550144 DOI: 10.1053/j.gastro.2022.05.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Pandey M, Lalwani A, Mehta R. Epigenetics of Breast Cancer. Breast Cancer: Current Trends in Molecular Research 2022. [DOI: 10.2174/9781681089522112010010] [Reference Citation Analysis]
5 Ghadiri Moghaddam F, Farajnia S, Karbalaei-Mahdi M, Monir L. Epigenetic insights in the diagnosis, prognosis, and treatment selection in CRC, an updated review. Mol Biol Rep 2022. [PMID: 35727475 DOI: 10.1007/s11033-022-07569-w] [Reference Citation Analysis]
6 Rogalska-Taranta M, Andersen JB. Involvement of Epigenomic Factors in Bile Duct Cancer. Semin Liver Dis 2022;42:202-11. [PMID: 35738258 DOI: 10.1055/s-0042-1748188] [Reference Citation Analysis]
7 Sinniah RS, Shapses MS, Ahmed MU, Babiker H, Chandana SR. Novel biomarkers for cholangiocarcinoma: how can it enhance diagnosis, prognostication, and investigational drugs? Part-1. Expert Opin Investig Drugs 2021;30:1047-56. [PMID: 34579607 DOI: 10.1080/13543784.2021.1985461] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Miari R, Azzam N, Bar-Shalom R, Fares F. 5-aza-2'-deoxycytidine induces apoptosis and inhibits tumour growth in vivo of FaDu cells, a specific HPVnegative HNSCC cell line. PLoS One 2021;16:e0253756. [PMID: 34534222 DOI: 10.1371/journal.pone.0253756] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Colyn L, Bárcena-Varela M, Álvarez-Sola G, Latasa MU, Uriarte I, Santamaría E, Herranz JM, Santos-Laso A, Arechederra M, Ruiz de Gauna M, Aspichueta P, Canale M, Casadei-Gardini A, Francesconi M, Carotti S, Morini S, Nelson LJ, Iraburu MJ, Chen C, Sangro B, Marin JJG, Martinez-Chantar ML, Banales JM, Arnes-Benito R, Huch M, Patino JM, Dar AA, Nosrati M, Oyarzábal J, Prósper F, Urman J, Cubero FJ, Trautwein C, Berasain C, Fernandez-Barrena MG, Avila MA. Dual Targeting of G9a and DNA Methyltransferase-1 for the Treatment of Experimental Cholangiocarcinoma. Hepatology 2021;73:2380-96. [PMID: 33222246 DOI: 10.1002/hep.31642] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
10 Lai J, Fu Y, Tian S, Huang S, Luo X, Lin L, Zhang X, Wang H, Lin Z, Zhao H, Lin S, Zhao J, Xu S, Li D, Cai S, Dong L, Qian J, Liang J, Li Q, Zhang Y, Fan J, Balderas R, Chen Q. Zebularine elevates STING expression and enhances cGAMP cancer immunotherapy in mice. Mol Ther 2021;29:1758-71. [PMID: 33571681 DOI: 10.1016/j.ymthe.2021.02.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
11 Navada SC. Therapeutics and DNA methylation inhibitors. Medical Epigenetics 2021. [DOI: 10.1016/b978-0-12-823928-5.00014-1] [Reference Citation Analysis]
12 Hu S, Molina L, Tao J, Liu S, Hassan M, Singh S, Poddar M, Bell A, Sia D, Oertel M, Raeman R, Nejak-bowen K, Singhi A, Luo J, Monga SP, Ko S. NOTCH-YAP1/TEAD-DNMT1 axis regulates hepatocyte reprogramming into intrahepatic cholangiocarcinoma.. [DOI: 10.1101/2020.12.03.410993] [Reference Citation Analysis]
13 Grippo PJ. A New SET Piece in Cancer Development. Gastroenterology 2020;159:437-9. [PMID: 32565016 DOI: 10.1053/j.gastro.2020.06.025] [Reference Citation Analysis]
14 Sanaei M, Kavoosi F. Effect of Zebularine in Comparison to and in Combination with Trichostatin A on CIP/KIP Family (p21Cip1/Waf1/Sdi1, p27Kip1, and p57Kip2), DNMTs (DNMT1, DNMT3a, and DNMT3b), Class I HDACs (HDACs 1, 2, 3) and Class II HDACs (HDACs 4, 5, 6) Gene Expression, Cell Growth Inhibition and Apoptosis Induction in Colon Cancer LS 174T Cell Line. Asian Pac J Cancer Prev 2020;21:2131-9. [PMID: 32711442 DOI: 10.31557/APJCP.2020.21.7.2131] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
15 Yin J. DNA Methyltransferase and its Clinical Applications. IOP Conf Ser : Earth Environ Sci 2020;512:012082. [DOI: 10.1088/1755-1315/512/1/012082] [Reference Citation Analysis]
16 Sanaei M, Kavoosi F. Investigation of the Effect of Zebularine in Comparison to and in Combination with Trichostatin A on p21Cip1/Waf1/ Sdi1, p27Kip1, p57Kip2, DNA Methyltransferases and Histone Deacetylases in Colon Cancer LS 180 Cell Line. Asian Pac J Cancer Prev 2020;21:1819-28. [PMID: 32592383 DOI: 10.31557/APJCP.2020.21.6.1819] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
17 Idrissou M, Sanchez A, Penault-Llorca F, Bignon YJ, Bernard-Gallon D. Epi-drugs as triple-negative breast cancer treatment. Epigenomics 2020;12:725-42. [PMID: 32396394 DOI: 10.2217/epi-2019-0312] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
18 Kozako T, Itoh Y, Honda S, Suzuki T. Epigenetic Control Using Small Molecules in Cancer. In: Bizzarri M, editor. Approaching Complex Diseases. Cham: Springer International Publishing; 2020. pp. 111-48. [DOI: 10.1007/978-3-030-32857-3_6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Shukla S, Penta D, Mondal P, Meeran SM. Epigenetics of Breast Cancer: Clinical Status of Epi-drugs and Phytochemicals. Adv Exp Med Biol 2019;1152:293-310. [PMID: 31456191 DOI: 10.1007/978-3-030-20301-6_16] [Cited by in Crossref: 30] [Cited by in F6Publishing: 16] [Article Influence: 10.0] [Reference Citation Analysis]
20 Sheng J, Shi W, Guo H, Long W, Wang Y, Qi J, Liu J, Xu Y. The Inhibitory Effect of (-)-Epigallocatechin-3-Gallate on Breast Cancer Progression via Reducing SCUBE2 Methylation and DNMT Activity. Molecules 2019;24:E2899. [PMID: 31404982 DOI: 10.3390/molecules24162899] [Cited by in Crossref: 34] [Cited by in F6Publishing: 39] [Article Influence: 11.3] [Reference Citation Analysis]
21 Rai V, Boosani C, Agrawal D. The promising role of epigenetic mediators and microRNAs in the early diagnosis of cholangiocarcinoma (Review). Wrld Acd Sci 2019. [DOI: 10.3892/wasj.2019.18] [Reference Citation Analysis]
22 Patnaik S, Anupriya. Drugs Targeting Epigenetic Modifications and Plausible Therapeutic Strategies Against Colorectal Cancer. Front Pharmacol. 2019;10:588. [PMID: 31244652 DOI: 10.3389/fphar.2019.00588] [Cited by in Crossref: 51] [Cited by in F6Publishing: 55] [Article Influence: 17.0] [Reference Citation Analysis]
23 Braconi C, Roessler S, Kruk B, Lammert F, Krawczyk M, Andersen JB. Molecular perturbations in cholangiocarcinoma: Is it time for precision medicine? Liver Int 2019;39 Suppl 1:32-42. [PMID: 30829432 DOI: 10.1111/liv.14085] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
24 Liu Y, Yan X. Eriodictyol inhibits survival and inflammatory responses and promotes apoptosis in rheumatoid arthritis fibroblast‐like synoviocytes through AKT/FOXO1 signaling. J Cell Biochem 2019;120:14628-35. [DOI: 10.1002/jcb.28724] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
25 Chen Y, Yang T, Zhou B, Yang M, Feng H, Wang Y. HOXA5 overexpression promotes osteosarcoma cell apoptosis through the p53 and p38α MAPK pathway. Gene 2019;689:18-23. [DOI: 10.1016/j.gene.2018.11.081] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
26 Daifuku R. Pharmacoepigenetics of Novel Nucleoside DNA Methyltransferase Inhibitors. Pharmacoepigenetics 2019. [DOI: 10.1016/b978-0-12-813939-4.00007-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
27 Eroglu O, Celik EG, Kaya H, Celen M, Karabicici M, Karacoban E. Investigation of Methylation Profiles of TP53, Caspase 9, Caspase 8, Caspase 3 Genes Treated with DNA Methyl Transferase Inhibitor (DNMTi) Zebularine (ZEB) and Caffeic Acid Phenethyl Ester (CAPE) on MCF-7 and MDA-MB-231 Breast Cancer Cell Lines. JCT 2019;10:69-85. [DOI: 10.4236/jct.2019.101006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
28 O’rourke CJ, Satriano L, Oliveira DV, Munoz-garrido P, Andersen JB. Therapeutic Potential of Pharmacoepigenetics in Cholangiocarcinoma. Pharmacoepigenetics 2019. [DOI: 10.1016/b978-0-12-813939-4.00017-6] [Reference Citation Analysis]
29 Eroglu O, Celen M. Investigation of the Effects of Zebularine on Caspase-3 and Caspase-9 Involved in Anticancer and Apoptotic Mechanisms in SKBR3 Breast Cancer Cell Line. JCT 2019;10:229-244. [DOI: 10.4236/jct.2019.103019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
30 Chen J, Li QY, Luo YH, Xiao EH. Continuous zebularine treatment enhances hepatic differentiation of mesenchymal stem cells under liver-specific factors induction in vitro. Life Sci 2018;215:57-63. [PMID: 30473025 DOI: 10.1016/j.lfs.2018.10.049] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
31 Chen Z, Guo P, Xie X, Yu H, Wang Y, Chen G. The role of tumour microenvironment: a new vision for cholangiocarcinoma. J Cell Mol Med. 2019;23:59-69. [PMID: 30394682 DOI: 10.1111/jcmm.13953] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
32 Pirola L, Ciesielski O, Balcerczyk A. The Methylation Status of the Epigenome: Its Emerging Role in the Regulation of Tumor Angiogenesis and Tumor Growth, and Potential for Drug Targeting. Cancers (Basel) 2018;10:E268. [PMID: 30103412 DOI: 10.3390/cancers10080268] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 6.3] [Reference Citation Analysis]
33 Agrawal K, Das V, Vyas P, Hajdúch M. Nucleosidic DNA demethylating epigenetic drugs – A comprehensive review from discovery to clinic. Pharmacology & Therapeutics 2018;188:45-79. [DOI: 10.1016/j.pharmthera.2018.02.006] [Cited by in Crossref: 66] [Cited by in F6Publishing: 68] [Article Influence: 16.5] [Reference Citation Analysis]
34 Takemura Y, Satoh M, Hatanaka K, Kubota S. Zebularine exerts its antiproliferative activity through S phase delay and cell death in human malignant mesothelioma cells. Biosci Biotechnol Biochem 2018;82:1159-64. [PMID: 29685095 DOI: 10.1080/09168451.2018.1459466] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
35 O'rourke CJ, Munoz-garrido P, Aguayo EL, Andersen JB. Epigenome dysregulation in cholangiocarcinoma. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2018;1864:1423-34. [DOI: 10.1016/j.bbadis.2017.06.014] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
36 Terranova-Barberio M, Thomas S, Munster PN. Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors. Immunotherapy 2016;8:705-19. [PMID: 27197539 DOI: 10.2217/imt-2016-0014] [Cited by in Crossref: 43] [Cited by in F6Publishing: 47] [Article Influence: 8.6] [Reference Citation Analysis]
37 Zhang J, Sang M, Gu L, Liu F, Li W, Yin D, Wu Y, Liu S, Huang W, Shan B. Zebularine Treatment Induces MAGE-A11 Expression and Improves CTL Cytotoxicity Using a Novel Identified HLA-A2-restricted MAGE-A11 Peptide. Journal of Immunotherapy 2017;40:211-20. [DOI: 10.1097/cji.0000000000000170] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
38 Nakaoka T, Saito Y, Saito H. Aberrant DNA Methylation as a Biomarker and a Therapeutic Target of Cholangiocarcinoma. Int J Mol Sci. 2017;18:1111. [PMID: 28545228 DOI: 10.3390/ijms18061111] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 5.2] [Reference Citation Analysis]
39 Huang S, Zheng C. Gene alterations and epigenetic changes in intrahepatic cholangiocarcinoma. Expert Review of Anticancer Therapy 2016;17:89-96. [DOI: 10.1080/14737140.2017.1266261] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
40 Pechalrieu D, Etievant C, Arimondo PB. DNA methyltransferase inhibitors in cancer: From pharmacology to translational studies. Biochem Pharmacol 2017;129:1-13. [PMID: 27956110 DOI: 10.1016/j.bcp.2016.12.004] [Cited by in Crossref: 66] [Cited by in F6Publishing: 54] [Article Influence: 11.0] [Reference Citation Analysis]
41 Zmarzły N, Wojdas E, Skubis A, Sikora B, Mazurek U. DNA methylation: gene expression regulation. FBOe 2016;12:1-10. [DOI: 10.1515/fobio-2016-0001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
42 Graça I, Pereira-Silva E, Henrique R, Packham G, Crabb SJ, Jerónimo C. Epigenetic modulators as therapeutic targets in prostate cancer. Clin Epigenetics 2016;8:98. [PMID: 27651838 DOI: 10.1186/s13148-016-0264-8] [Cited by in Crossref: 43] [Cited by in F6Publishing: 48] [Article Influence: 7.2] [Reference Citation Analysis]
43 Zhao S, Wu J, Tang Q, Zheng F, Yang L, Chen Y, Li L, Hann SS. Chinese herbal medicine Xiaoji decoction inhibited growth of lung cancer cells through AMPKα-mediated inhibition of Sp1 and DNA methyltransferase 1. Journal of Ethnopharmacology 2016;181:172-81. [DOI: 10.1016/j.jep.2016.01.041] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
44 Bhalla S, Navada S. Therapeutics and DNA Methylation Inhibitors. Medical Epigenetics 2016. [DOI: 10.1016/b978-0-12-803239-8.00033-8] [Reference Citation Analysis]